

# 1988



**Ms. Linda  
Grass**

Years in Lab: 1988 – 2006

Most important publications: Not applicable

Citation: Linda Grass was Laboratory Manager of the ACDC Laboratory from 1988 – 2006. Linda was instrumental in organizing and directing the early days of the ACDC Laboratory and participated in it's extension for over 15years. She not only performed many experiments, but she also handled finances, and mentored many graduate students over that period.

# 1989



**Dr. Theodore  
Christopoulos**

Years in Lab: 1986 – 1992

Most important publications: Anal Chem 1990; 62: 360-7

Anal Chem 1990; 62: 1449A – 1157A

Citation: Theodore was the first Graduate Student (Athens, Greece) and the first Post-Doctoral Fellow (Toronto, Canada) of Dr. Diamandis. He is a superb analytical chemist who contributed to the development of ultrasensitive immunological assays for many analytes by using time resolved flurometry. He continued his own career as Professor of Analytical Chemistry at the University of Patras, Greece.

1990



**Dr. Evi S.  
Lianidou**

Years in Lab: 1989 – 1997

Most important publications: Urology 1999; 54: 753-62

Clin Chem 1990; 36:1679-83

Citation: Evi completed 2 Post-Doctoral Fellowship in the ACDC laboratory and worked towards developing ultrasensitive assays for various analytes by using time resolved fluorescence and was the first to identify BRCA1 immunoreactivity in human seminal plasma. She is now a full professor with her own research program at the University of Athens, Greece.

# 1991



**Dr. Sotirios  
Kakabakos**

Years in Lab: 1990 – 1991

Most important publications: Clin Chem 1992; 38: 338-42

Citation: Sotirios completed a Post-Doctoral Fellowship between 1990 – 1991 and he was instrumental in developing one of the first multianalyte immunoassays by using specialized-immobilized antibodies from plastic surfaces. He was able to quantify 4 analytes simultaneously with very high sensitivity and specificity. His was one of the first examples of “microarray-type” assay based on surface fluorescence.

# 1992



**Dr. Stavroula  
Hassapoglidou**

Years in Lab: 1990 – 1992

Most important publications: Oncogene 1993; 8: 1501-9  
Clin Biochem 1992; 25: 445-9

Citation: Stavroula was the first to develop an ELISA-type assay for measuring p53 tumour suppressor protein autoantibody in biological fluids. She was able to show p53 autoantibody positivity in a small fraction of breast and other cancers.

**1993**



**Dr. Katerina  
Angelopoulou**

Years in Lab: 1992 – 1998

Most important publications: Int J Cancer 1994;  
58: 480-7

Cancer 1996; 78: 2146-52

Citation: For identification of p53 auto antibodies  
in a wide variety of cancers and development of the  
concept of auto antibodies in panels may serve as  
novel diagnostic cancer biomarkers

1994



**Dr. Ramon  
Evangelista**

Years in Lab: 1992

Most important publications: Clin Biochem 1988; 21: 173-8

Citation: Ramon was an outstanding synthetic-organic chemist who synthesized the legendary European Fluorescence Chelate – BCPDA – in the late 1980s. This European chelater formed the basis of many time-resolved fluorescence immunoassays that were developed by Diamandis and his group in the early 1990s, first at CyberFluor and then at the University of Toronto.

1995



**Dr. Herbert  
(He) Yu**

Years in Lab: 1992 – 1996

Most important publications: J Biol Chem 1995; 270:6615-8

Cancer Res 1995; 55: 2104-10

Citation: Herb Yu was an outstanding epidemiologist and biostatistician who discovered non-prostatic PSA and has shown that PSA in breast cancer has prognostic significance. He also contributed to many other projects including ultrasensitive PSA monitoring in prostate cancer patients in growth factors and their binding proteins. He is now a Professor at the University of Hawaii.

1996



**Dr. Michael A.  
Levesque**

Years in Lab: 1992 – 1999

Most important publications: J Clin Oncol 1998;  
16: 2641 - 50

Int J Cancer 1998; 79: 494 - 501

Citation: Michael was the first to develop a sensitive ELISA assay for p53 tumour suppressor protein and examine it's prognostic value in various types of cancer.

# 1997



**Dr. Dimitrios  
N. Melegos**

Years in Lab: 1994 – 1998

Most important publications: Urology 1999;53:32-7

Clin Chem 1998;44:691-2

Citation: The most important contributions of Dimitrios was the demonstration of prostaglandin D synthase is increased in serum of patients with renal failure and he demonstrated for the first time that prostate specific antigen is present in female serum at detectable concentrations.

# 1998



**Dr.  
George  
Soleas**

Years in Lab: 1994 – 2002

Most important publications: *Methods Enzymol*  
2001;335:145-54

*Anal Chem* 1997;69:4405-9

Citation: George was the first to develop robust analytical methodologies based on mass spectrometry for quantifying resveratrol and other phenolic constituents in wine. He has also shown that resveratrol is absorbed by humans and may be the mediator of the beneficial effects of wine for human health.

1999



**Dr. Debbie  
Tsuyuki**

Years in Lab: 1996

Most important publications: Eur J Cancer 1997;  
33: 1851-4

Clin Cancer Res 1997;3:1201-6

Citation: Debbie was the first true molecular biologist in Dr. Diamandis' laboratory and assisted in demonstrating expression of prostate specific antigen by non-prostatic tissues using molecular technologies.

2000



**Dr. Liu-Ying  
Luo**

Years in Lab: 1997 – 2004

Most important publications: Cancer Res 2003; 63: 807-11 / Clin Cancer Res 2001;7:2372-9 / Biochem Biophys Res Comm 1998; 247:580-6

Citation: Liu-Ying was the first to characterize human kallikrein 10 and has shown that it is an excellent biomarker for ovarian carcinoma. She also cloned many other genes in the Diamandis Laboratory in the late 1990s and early 2000s

2001



**Ms. Hassima  
Omar-Ali**

Years in Lab: 1997 – Present

Citation: Hassima has been working with ACDC Laboratory for more than 15 years and she has an outstanding job as a secretary, supporting the whole staff of the ACDC laboratory.

**2002**



**Dr. Christina  
V. Obiezu**

Years in Lab: 1997 – 2004

Most important publications: J Urol 2000;163:802-5

J Clin Endocrinol Metab 2001;86:1558-61

Citation: Christina had shown for the first time that PSA and human glandular kallikrein 2 (hK2) marker is elevated in urine of patients with polycystic ovary syndrome and also demonstrated dramatic elevations of PSA and KLK2 in urine and serum of female-to-male transsexuals. She also contributed significantly to the KLK4 literature.

**2003**



**Dr. George  
M. Yousef**

Years in Lab: 1998 – 2002

Most important publications: J Biol Chem 1999; 274: 37511-6 / J Biol Chem 2000; 275: 11891-8 / J Biol Chem 2001; 276: 53-61

Citation: George is credited with the cloning of many novel kallikrein and other genes, the characterization of the kallikrein locus and the demonstration that many of these genes are regulated by steroid hormones and can act as effective cancer biomarkers

2004



**Mr. *Antoninus*  
Soosaipillai**

Years in Lab: 1998 – Present

Most important publications: Not Applicable

Citation: For providing excellent support for over 10 years and then, since 2008 acting as an effective research coordinator managing all operations of the ACDC Laboratory

**2005**




**Ms.  
Tammy  
Earle**

**Years in Lab: 2005 – 2008**

**Most important publications: Not Applicable**

**Citation: Tammy was a very effective research coordinator of the ACDC Laboratory for three years. During this period she assisted numerous graduate students and post-doctoral fellows and managed effectively the ACDC Laboratory**

**2006**



**Dr. George  
Foussias**

Years in Lab: 1999 – 2001

Most important publications: Genomics.  
2000;67(2):171-8 / Biochem Biophys Res Commun.  
2001;284(4):887-99.

Citation: George was instrumental in cloning members of the Siglec family and characterizing their biological activities. Awarded with Dr. Diamandis an NSERC grant for genomic characterization of the Siglec locus.

2007



**Dr. Carla A.  
Borgoño**

Years in Lab: 2000 – 2006

Most important publications: Nat Rev Cancer. 2004;4(11):876-90 / J Biol Chem. 2007;282(4):2405-22 / J Biol Chem. 2007;282(6):3640-52.

Citation: Carla was instrumental in characterizing proteolytic activity of kallikrein 14 and delineate its role in skin and other organ physiology. She wrote the most influential and cited kallikrein review in Nat Rev Cancer in 2004.

2008




*Dr. Iacovos P.  
Michael*

Years in Lab: 2002 – 2005

Most important publications: J Biol Chem  
2006;281:12743-50 / J Biol Chem  
2005;280:14628-35 / Mol Can Res 2004;2:257-80

Citation: Iacovos characterized enzymatic activity of human kallikrein 5 and showed that it participates in the seminal plasma cascade and in cancer progression.

**2009**



**Dr. Marc B.  
Elliott**

Years in Lab: 2003 – 2005

Most important publications: Genomics.  
2006;88(5):591-9

Biochim Biophys Acta. 2004;1698(1):77-86

Citation: Mark was one of the first to perform phylogenetic analysis of the kallikrein locus in human and other species. He identified homologues within this family.

2010



**Dr.  
Nashmil  
Emami**

Years in Lab: 2005 – 2008

Most important publications: J Biol Chem. 2008;283(28):19561-9 / J Biol Chem. 2008;283(6):3031-41

Citation: Nashmil was the first to show the major role of human kallikrein 14 in seminal clot liquefaction and skin desquamation. She delineated how KLK14 participate in the seminal plasma proteolytic cascade and the skin proteolytic cascade.

2011



**Dr. Jane  
Chan-  
Kyung Cho**

Years in Lab: 2006 – 2010

Most important publications: Mol Cell Proteomics.  
2007;6(8):1406-15.

J Proteome Res. 2010;9(7):3574-82

Citation: Jane was the first to delineate the  
amniotic fluid proteome and identify potential  
biomarkers in amniotic fluid for diagnosis of  
Down Syndrome

**2012**



**Dr. Katerina  
Oikonomopou  
lou**

**Years in Lab: 2002 – 2009**

**Most important publications: J BiolChem. 2006;281(43):  
32095-112 / J Immunol. 2013;191:3858-66**

**Citation: Katerina was the first to show, in  
collaboration with Dr. Morley Hollenberg, University of  
Calgary that certain kallikreins can activate or  
deactivate proteinase-activated receptors (PARs). These  
findings have now been substantiated by many other  
groups.**

2013



**Dr. Vathany  
Kulasingam**

Years in Lab: 2004 – 2008

Most important publications: Nat Rev Cancer. 2010;10(5):371-8 / Nat Clin Pract Oncol. 2008;5(10):588-99 / Mol Cell Proteomics. 2007;6(11):1997-2011

Citation: Vathany was the first to systematically standardize our proteomic methods for biomarker discovery and wrote influential reviews on how to discover cancer biomarkers by using mass spectrometry.

**2014**



**Dr. Andreas  
Scorilas**

Years in Lab: 1998 – 2000

Most important publications: Br J Cancer.  
2001;85(2):190-8 / Genomics. 2001;72(2):217-21 /  
Clin Cancer Res. 1999;5(7):1778-85.

Citation: Andreas cloned a number of different  
genes adjacent to the kallikrein locus and assisted  
in the statistical validation of many papers  
published by the ACDC Lab over the last decade.

**2015**



**Shalini  
Makawita**

Years in Lab: 2008 – 2011

Most important publications: Mol Cell Proteomics.  
2011;10(10):M111.008599 / Clin Chem.  
2010;56(2):212-22

Citation: Shalini performed deep proteomic analysis of pancreatic cell lines, supernatants, pancreatic juice, pancreatic cancer ascites and identified novel biomarkers for diagnosis and monitoring of pancreatic carcinoma.